BREYANZI: CAR T-Cell Therapy for The Treatment of B Cell Lymphoma

BREYANZI: Immunotherapy for The Treatment of B Cell Lymphoma

INDICATIONS AND USAGE

BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma.

DOSAGE AND ADMINISTRATION

For autologous use only. For intravenous use only.

• Do NOT use a leukodepleting filter.

• Administer a lymphodepleting regimen of fludarabine and cyclophosphamide before infusion of BREYANZI.

• Verify the patient’s identity prior to infusion.

• Premedicate with acetaminophen and an H1 antihistamine.

• Confirm availability of tocilizumab prior to infusion.

• Dosing of BREYANZI is based on the number

• The dose is 50 to 110 × 106 CAR-positive viable T cells (consisting of CD8 and CD4 components) .

• Administer BREYANZI in a certified healthcare facility.

DOSAGE FORMS AND STRENGTHS

• BREYANZI is a cell suspension for infusion.

•A single dose of BREYANZI contains 50 to 110 × 106 CARpositive viable T cells (consisting of 1:1 CAR-positive viable T cells of the CD8 and CD4 components), with each component supplied separately in one to four single-dose 5 mL vials. Each mL contains 1.5 × 106 to 70 × 106 CAR-positive viable T cells.

CONTRAINDICATIONS

None (4).

WARNINGS AND PRECAUTIONS

• Hypersensitivity Reactions: Monitor for hypersensitivity reactions during infusion.

• Serious Infections: Monitor patients for signs and symptoms of infection; treat appropriately.

• Prolonged Cytopenias: Patients may exhibit Grade 3 or higher cytopenias for several weeks following BREYANZI infusion. Monitor complete blood counts.

• Hypogammaglobulinemia: Monitor and consider immunoglobulin replacement therapy.

• Effects on Ability to Drive and Use Machines: Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery for at least 8 weeks after BREYANZI administration.

ADVERSE REACTIONS

The most common non-laboratory adverse reactions (incidence greater than or equal to 20%) in BREYANZI-treated patients were fatigue, cytokine release syndrome, musculoskeletal pain, nausea, headache, encephalopathy, infections (pathogen unspecified), decreased appetite, diarrhea, hypotension, tachycardia, dizziness, cough, constipation, abdominal pain, vomiting, and edema.

Box Warning

• Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving BREYANZI. Do not administer BREYANZI to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids.

• Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving BREYANZI, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with BREYANZI. Provide supportive care and/or corticosteroids as needed.

• BREYANZI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.

Source

https://www.fda.gov/media/145711/download

Carbohydrate Metabolism: MCQs and answers on Glycolysis & Gluconeogenesis

MCQ on Glycolysis & Gluconeogenesis 1) Which of the following enzyme is not involved in galactose metabolism? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 2) Which of the following enzyme is defective in galactosemia (type I) - a fatal genetic disorder in infants? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 3) In the liver, the accumulation of which of the following metabolite attenuates the inhibitory of ATP on phosphofructokinase? a) Glucose-6-Phosphate b) Citrate c) Fructose-1,6-Bisphosphate d) Fructose-2,6-Bisphosphate 4) Mutation in which of the following enzymes leads to a glycogen storage disease known as "Tarui’s disease"? a) Glucokinase b) Phosphofructokinase c) Phosphoglucomutase d) Pyruvate Kinase 5) E...

MCQs and Answers on cultivation (culture/incubation), Isolation and Identification of microorganisms: Medical Microbiology

40 plus questions - Multiple Choice Questions on Classification, Culture, and Identification of the microorganisms 1. Which of the following microorganism has the cocci cell shapes and sizes arranged usually in tetrad structures? a) Streptococcus pneumoniae b) Staphylococcus aureus c) Chlamydia trachomatis d) Neisseria meningitidis 2. What are the different growth morphology and cell structures used for the classification of fungi? Select all the correct answers: a) Yeast b) Mold c) Mycelia d) Protozoa 3. Which of the following media is formulated with additional nutrients to support the growth of fastidious or nutritionally demanding bacteria that may not grow well on basic media? a) Differential media b) Enriched media c) Nutrient agar (media) d) Selective media 4. Which of the following metabolic characteristic is a distinguishing characteristic and identification of colonies of E. coli ? a) Hydrogen sulfide formation b) Indole Formation c) Lactose fe...

MCQs on Bacterial Pathogenesis: Medical Microbiology

Key aspects of Bacterial pathogenesis/ General steps in bacterial pathogenesis Adherence and Colonization Invasion Immune Evasion Toxin Production Nutrient Acquisition Host Cell Manipulation Inflammation and Tissue Damage Multiple Choice Questions on Bacterial Pathogenesis Figure 1: Phagocyte activity and possible outcomes of phagocyte-bacterial interactions (Source/Reference: Bailey & Scott’s Diagnostic Microbiology) 1) Which of the following microorganism is the major inhabitant of the human skin? a) Escherichia coli b) Staphylococcus epidermidis c) Staphylococcus aureus d) Streptococcus pyogenes 2) Select all the medically important bacteria which are frequently isolated pathogen human infections? a) Enteric ba...

BIOCHEMISTRY, BIOMEDICINE & PHARMACEUTICS

Search This Blog